Thank you for downloading this publication. Please let us know why you chose this publication:
Why are you interested in this publication?
What organisation do you represent?
You will only need to complete this form once per browser/device
How do you prefer to read or receive publications?

We may contact you for feedback on the publication you have downloaded. If you do not want to be contacted, please leave the email field blank. Your information will never be shared with any third party.

Malaria Consortium US Donate
  • About us
    • Who we are
    • Our Strategy
    • Governance
    • Aid transparency
  • Projects
  • Where We Work
  • What we do
    • Diseases
    • Our responses
    • Burden reduction to elimination
    • Data-informed decision-making & digital approaches
    • Health sector resilience
    • Research & policy change
    • Networks & partnerships
  • News & Resources
    • News
    • Blog
    • Videos
    • Webinars
    • Photo stories
  • Publications
    • Interactive publications
  • Support us
  • Contact Us
    • Newsletter
  • Work with us
    • Tenders
  • Home
  • »

Share this page

Projects

Database

Projects Database
View Project brief

Project

Improving severe malaria outcomes

A consortium of partners, comprising Medicines for Malaria Venture, Clinton Health Access Initiative, Partnership for Supply Chain Management and Malaria Consortium have developed this project to improve malaria outcomes through improving access to injectable artesunate and intrarectal artesunate.
The project will support the increase in uptake and use of injectable artesunate (Inj AS) and bring quality intrarectal artesunate to patients for pre-referral treatment of severe malaria. The consortium partners
will undertake a series of coordinated, parallel market interventions addressing key barriers on both the supply and demand side of the market for Inj AS in six countries: Cameroon, Ethiopia, Kenya, Malawi, Nigeria and Uganda.

Malaria Consortium, in collaboration with the beneficiary country programmes, will implement country-level activities in Ethiopia, Nigeria and Uganda and conduct operational research to assess whether using rectal artesunate or injectable artesunate will increase the use of monotherapies and thus increase the risk of developing resistance to artemisinins as malaria treatment.

Start Date:05/06/2013End Date:04/06/2016Countries:Ethiopia, Nigeria, UgandaRegion:AfricaKeywords:malaria, operational research,MalariaDonor:UNITAIDBudget: 3,205,828 (USD)Prime Recipient:Medicines for Malaria Venture

 

Back

Resources

  • Contact us
  • Latest news
  • Media centre
  • Aid transparency

Malaria Consortium Strategy 2021-2025

Related Resources

Photo for: Improving severe malaria outcomes Resource: Project brief
Published 20 January 2014

Improving severe malaria outcomes
Photo for: Reducing deaths from severe malaria Resource: Technical brief
Published 31 December 2013

Reducing deaths from severe malaria
Follow us on our social channels
  • Jobs
  • Contact us
  • Annual reviews
  • Support us
  • About us
  • Sitemap
  • Policies
  • Modern Slavery Statement
Fundraising Regulator logo
© 2023 Malaria Consortium | Charity No. 1099776 | Company No. 4785712